BeiGene
BGNE
#963
Rank
A$32.03 B
Marketcap
$282.29
Share price
1.02%
Change (1 day)
8.35%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : A$1.76 Billion

According to BeiGene 's latest financial reports the company's total debt is A$1.76 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$1.36 B55.71%
2022-12-31A$0.87 B-8.49%
2021-12-31A$0.95 B31.1%
2020-12-31A$0.73 B84.5%
2019-12-31A$0.39 B40.65%
2018-12-31A$0.28 B33.48%
2017-12-31A$0.21 B779.9%
2016-12-31A$23.97 M-15.96%
2015-12-31A$28.53 M68.75%
2014-12-31A$16.9 M-44.88%
2013-12-31A$30.67 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.81 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA